FindTrial
Sign In

Difference between the measured and predicted plasma concentration of remifentanil during target-controlled infusion in patients with different body fat percentages

Difference between the measured and predicted plasma concentration of remifentanil during target-controlled infusion in patients with different body fat percentages

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071720
Enrollment
Unknown
Registered
2023-05-23
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high body fat percentage

Interventions

Group of high body fat percentage (Remifentanil was administered by target-controlled infusion):None
Group of low body fat percentage (Remifentanil was administered by target-controlled infusion):None

Sponsors

Shanghai Fourth People's Hospital, Affiliated to Tongji University, Shanghai, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 18-65 years, ASA I-II, BMI 19-28 kg/m2, scheduled for selective surgery under general anesthesia.

Exclusion criteria

Exclusion criteria: Pacemaker implantation, patient unable to stand upright, severe cardiovascular disease, disease of liver and kidney function, history of alcohol or opioid abuse, patient refused.

Design outcomes

Primary

MeasureTime frame
Plasma concentration of remifentanil;body fat percentage;—

Secondary

MeasureTime frame
blood pressure;heart rate;—

Countries

China

Contacts

Public ContactGuanghui An

Shanghai Fourth People's Hospital

gh_An@163.com+86 137 6412 2642

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026